Cue Biopharma, Inc. Interest Expense
Cue Biopharma, Inc. (CUE) reported Interest Expense of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-14
- Cue Biopharma, Inc. interest expense for the quarter ending 2025-06-30 was $33.00K.
- Cue Biopharma, Inc. interest expense for the quarter ending 2025-03-31 was $100.00K, a 203.03% increase year-over-year.
- Cue Biopharma, Inc. interest expense for the quarter ending 2024-03-31 was $33.00K, a 0.00% change year-over-year.
- Cue Biopharma, Inc. interest expense for the quarter ending 2023-12-31 was -$748.00K, a 6900.00% decline year-over-year.
- Cue Biopharma, Inc. interest expense for fiscal 2025 was $100.00K, a 0.00% change from fiscal 2024.
- Cue Biopharma, Inc. interest expense for fiscal 2024 was $100.00K, a 0.00% change from fiscal 2023.
- Cue Biopharma, Inc. interest expense for fiscal 2023 was $100.00K, a 8.26% decline from fiscal 2022.
- Cue Biopharma, Inc. interest expense for fiscal 2022 was $109.00K.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-03-16 | ||||||
| 2025-06-30 | $33.00K 10-Q · filed 2026-08-14 | $65.00K 10-Q · filed 2026-08-14 | |||||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-14 | ||||||
| 2024-12-31 | $100.00K 10-K · filed 2026-03-16 | ||||||
| 2024-03-31 | $33.00K 10-Q · filed 2024-05-09 | -$715.00K derived: sum of 2 quarters · filed 2025-03-31 | -$461.00K derived: sum of 3 quarters · filed 2025-03-31 | -$111.00K derived: sum of 4 quarters · filed 2025-03-31 | |||
| 2023-12-31 | -$748.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$494.00K derived: sum of 2 quarters · filed 2025-03-31 | -$144.00K derived: sum of 3 quarters · filed 2025-03-31 | $100.00K 10-K · filed 2025-03-31 | $130.00K 10-K · filed 2024-03-28 | ||
| 2023-09-30 | $254.00K 10-Q · filed 2023-11-03 | $604.00K derived: sum of 2 quarters · filed 2023-11-03 | $848.00K 10-Q · filed 2023-11-03 | $648.00K derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2023-06-30 | $350.00K 10-Q · filed 2023-08-08 | $383.00K derived: sum of 2 quarters · filed 2024-05-09 | $394.00K derived: sum of 3 quarters · filed 2024-05-09 | $427.00K derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2023-03-31 | $33.00K 10-Q · filed 2024-05-09 | $330.42K 10-Q · filed 2023-05-09 | $44.00K derived: sum of 2 quarters · filed 2024-05-09 | $77.00K derived: sum of 3 quarters · filed 2024-05-09 | $110.00K derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $44.00K derived: sum of 2 quarters · filed 2024-03-28 | $77.00K derived: sum of 3 quarters · filed 2024-03-28 | $109.00K 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $33.00K 10-Q · filed 2023-11-03 | $124.00K 10-Q · filed 2022-11-14 | $66.00K derived: sum of 2 quarters · filed 2023-11-03 | $98.00K 10-Q · filed 2023-11-03 | $355.00K 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $33.00K 10-Q · filed 2023-08-08 | $206.00K 10-Q · filed 2022-08-04 | $230.00K 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $25.00K 10-Q · filed 2022-05-10 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |